Keay Nakae

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session.  Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board...

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets.  The Analyst Chardan analyst Keay Nakae started coverage of Dicerna with a Neutral rating and no price target...

Novavax, Inc. (NASDAQ: NVAX) popped 31 percent Wednesday evening after management announced the NanoFlu Vaccine demonstrated improved immune responses over alternative flu vaccines. Biotech experts disputed the data’s significance, with STAT News' Adam Feuerstein confessing skepticism. I...

Two analysts reiterated their Neutral ratings on Novavax, Inc. (NASDAQ: NVAX) after the company announced what it said was positive data for its phase 2 safety and immunogenicity trial of its RSV F vaccine. Novavax was down 24.5 percent and trading at $1.14 at the time of writing, one day after...

Shares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...

Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) reported additional encouraging results from the Phase 1b/2a clinical study of its lead product, EGP-437, in patients who have undergone cataract surgery. Terming the lead compound as “promising,” Chardan Capital Markets' Keay Nakae...

Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, saying the company "has the potential to become a significant competitor in the emerging fields of cell therapy and regenerative medicine." "Asterias is developing...

Chardan Capital’s Keay Nakae has initiated coverage of Mesoblast limited (ADR) (NASDAQ: MESO) with a Neutral rating and price target of $5.50. Nakae believes that there are several positives for the company, such as its proprietary mesenchymal lineage adult stem cells (MLCs), which can be...

Shares of Nanosphere, Inc. (NASDAQ: NSPH) are up approximately 10 percent on Tuesday trading, following the FDA provided 510(k) clearance for its Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex). According to a press release, “The first test of its kind, RP Flex features...